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Abstract Cardiac positron emission tomography (PET) is
mainly applied in myocardial perfusion and viability
detection. Noninvasive imaging of myocardial innervation
using PET is a valuable additional methodology in cardiac
imaging. Novel methods and different PET ligands have
been developed to measure presynaptic and postsynaptic
function of the cardiac neuronal system. Obtained PET data
can be analysed quantitatively or interpreted qualitatively.
Thus far, PET is not a widely used clinical application in
autonomic heart imaging; however, due to its technical
advantages, the excellent properties of the imaging agents,
and the availability of tools for quantification, it deserves a
better position in the clinic. From a historical point of view,
the focus of PET software packages for image analysis was
mainly oncology and neurology driven. Actually, com-
mercially available software for cardiac PET image anal-
ysis is still only available for the quantification of
myocardial blood flow. Thus far, no commercial software
package is available for the interpretation and quantifica-
tion of PET innervation scans. However, image data
quantification and analysis of kinetic data can be performed
using adjusted generic tools. This paper gives an overview
of different neuronal PET ligands, interpretation and
quantification of acquired PET data.
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Introduction
Positron emission tomography (PET) is successfully used
in cardiac applications since the 1980s and showed the
potential of this technique for the characterisation of
myocardial perfusion and metabolism. In the beginning as
a research tool, but later PET has been developed as a
clinical imaging tool.
PET scanning has also been established for cardiac
autonomic innervation assessment, mainly in the research
setting. It holds true that PET conveys higher method-
ological demands as well as less general availability.
Nevertheless, high spatial and temporal resolution together
with sequential attenuation correction considerably
improves the quality of the scans and, therefore, resulting
in higher accuracy as compared with SPECT [1]. Further-
more, PET enables regional absolute quantification from
dynamic data [2]. There is also increasing need for non-
invasive identification of new and refinement of existing
methods of risk stratification to particularly identify
patients at risk for ventricular tachyarrhythmia’s and car-
diac death. The presence of disrupted cardiac sympathetic
innervation is a predictor of future sudden cardiac death
after myocardial infarction [3]. PET, being the most opti-
mal technique for imaging sympathetic innervation, can be
applied to identify patients at high risk of fatal arrhythmias
[4]. At present, an implantable cardioverter defibrillator
(ICD) is the most effective treatment option to prevent
death from ventricular arrhythmia, and it is superior com-
pared to the use of anti-arrhythmic drugs alone [5–7].
However, not all patients eventually suffer from ventricular
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arrhythmia. Actually, the minority of patients (approxi-
mately 30 %) benefit from prophylactic ICD treatment.
There is a clinical need for better identification of those
patients at risk for life-threatening arrhythmia and thus
successful ICD therapy.
The available PET radiotracers enable the evaluation of
both the presynaptic and postsynaptic parts of the
myocardial autonomic innervation. Taking this in account,
PET offers an attractive methodology for innervation
assessment. This paper gives an overview of different
neuronal PET ligands, interpretation and quantification of
acquired PET data.
PET ligands to imaging the autonomic myocardial
function
Presynaptic sympathetic innervation
A number of radiotracers have been developed, evaluated
and deployed targeting presynaptic neuronal function (up-
take-1 norepinephrine reuptake pathway), postsynaptic a-
and b-adrenoceptor density, and second messenger systems
(adenylate cyclase/cyclic AMP and phospholipase C/inos-
itol trisphosphate cascades). While the majority of clinical
applications to date have utilised analogues of nore-
pinephrine including iodine-123 labelled metaiodobenzyl-
guanidine ([123I]-MIBG) with SPECT, the most commonly
used PET tracer for imaging of presynaptic sympathetic
function is carbon-11 labelled meta-hydroxyephinephrine
([11C]-mHED), which is also a norepinephrine analogue. In
contrast to the other PET tracers [11C]-epinephrine and
[11C]-phenylephrine, [11C]-mHED is not susceptible to
breakdown by monoamine oxidase and catechol-O-
methyltransferase. For [11C]-mHED, this does not result in
radiolabelled metabolites and, therefore, no need for
metabolite correction, which is necessary for [11C]-epi-
nephrine and [11C]-phenylephrine [8, 9].
More recently, a PET analogue of MIBG has been
developed and analysed, attempting to capitalise on the
clinical experience with the iodinated SPECT analogue and
the higher spatial resolution of PET. The compound, N-[3-
bromo-4-(3-[18F]-fluoro-propoxy)-benzyl]-guanidine ([18F]
LMI1195) which can be easily labelled by direct [18F]-
fluorination of a brosylate precursor, has undergone pre-
clinical testing, in which cardiac uptake was well defined
compared to liver. Imaging studies in rabbits with desi-
pramine blockade or 6-hydroxydopamine denervation
demonstrated a correlation between [18F]-LMI1195 reten-
tion and uptake-1 density without a corresponding differ-
ence in myocardial blood flow for either model [10].
Recently, a human safety, whole-organ biodistribution, and
radiation dosimetry of [18F]-LMI1195 (Fig. 1) were eval-
uated in a phase 1 clinical trial [11]. These preliminary data
suggest that [18F] LMI1195 is well tolerated and yields a
radiation dose comparable to that of other commonly used
PET radiopharmaceuticals.
Postsynaptic sympathetic innervation
In addition to presynaptic sympathetic innervation imaging
using norepinephrine analogues, it is also possible to
measure postsynaptic b-adrenoceptor density on the car-
diomyocyte. Changes in b-adrenoceptor density are of
Fig. 1 Representative sequence of whole-body LMI1195 coronal
images at mid-myocardial level in human volunteer. Each whole-
body image is scaled to maximum value within that image. This
research was originally published in JNM. Sinusas AJ, Lazewatsky J,
Brunetti J, Heller G, Srivastava A, Liu YH, Sparks R, Puretskiy A,
Lin SF, Crane P, Carson RE, Lee LV. Biodistribution and radiation
dosimetry of LMI1195: first-in-human study of a novel 18F-labeled
tracer for imaging myocardial innervation. J Nucl Med.
2014;55:1445–1451.  by the Society of Nuclear Medicine and
Molecular Imaging, Inc
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importance in the development of heart failure: b-adreno-
ceptor density is downregulated as a consequence of
enhanced sympathetic drive in heart failure [12, 13].
However, the clinical use of these receptor–ligands has
been limited to only a few studies and still faces significant
challenges. At present, [11C]-CGP-12177 is the most
widely used PET tracer for imaging b-adrenoceptor density
[14, 15]. This tracer is suggested feasible for clinical utility
due to high receptor affinity and fast plasma clearance.
However, its synthesis is rather complicated. The isopropyl
analogue of [11C]-CGP-12177 S-4-(3-([11C]-isopropy-
lamino)-2-hydroxypropoxy)-2H-benzimidazol-2-one ([11C]-
CGP12388) can be labelled easier and has a similar
biodistribution and retention as [11C]-CGP-12177 [16, 17].
[11C]-CGP-12388 has the potential to monitor b-adreno-
ceptor remodelling induced by therapeutic regimen. How-
ever, this has not yet been visualized. Recent developments
have led to the introduction of [18F] labelled b1-adrenocepter
antagonist ICI89406 ([18F]-FICI); unfortunately, this PET
compound proofed to be aspecific [18]. The frequency of b-
blocker therapy in heart failure population limits the utility
of adrenoceptor radioligands, as accurate quantitative
imaging necessitates discontinuation of this therapy. As
such, there has been exploration of the potential to image
signal transduction following adrenergic receptor stimula-
tion. While few of these compounds have yet been evaluated
in a clinical setting, the preclinical evidence supports long-
term development of multitracer studies, including candidate
radiotracers of intracellular signalling, for instance [11C]-
rolipram [19–21].
Parasympathetic innervation
The parasympathetic nervous system is the autonomic
counterpart of the sympathetic or adrenergic nervous
system, and consists of a dense network of nerves with
widespread distribution of muscarinic and nicotinic
receptors, which mediate the response to released
acetylcholine. At present, two PET tracers have been
clinically validated for invasive imaging of parasympa-
thetic innervation. These tracers are the highly specific
muscarinic receptor antagonist [11C]-MQNB and the
nicotinic agonist 2-[18F]-F-A-85380 [22, 23]. A derivate
of the selective antagonist of vesicular acetylcholine
transporters has only been used in a preclinical setting
[24]. Very recently, some exploratory experience was
gained on the visualisation of nicotinic acetylcholine
receptors in the vascular wall, which are also stimulated
by exogenous nicotine [25, 26]. Additional studies are
needed to assess its value in parasympathetic innervation
imaging.
PET data analysis and interpretation
[11C]-mHED
In short, acquisition of data occurs after injection of
approximately 350 MBq (range 200–400 MBq) of [11C]-
mHED (Fig. 3). During dynamic imaging for 60 min, heart
rate and blood pressure are monitored continuously. Since
retention of [11C]-mHED is dependent on myocardial
perfusion, a myocardial perfusion PET should always be
performed before the [11C]-mHED acquisition. Acquired
data are then corrected for attenuation and for residual
perfusion PET tracer activity.
Originally, kinetic analysis of [11C]-mHED data was
performed according to compartment models, which
require good understanding of the different compartments
to which the tracer is distributed. Different compartments
are connected by rate constants, which describe the
exchange of tracer between them, using blood sampling
(arterial preferable) as input and reference. The different
equations, measured blood and tissue activity curves, and
consequent estimated rate constant, make compartment
models complex and susceptible to noise, As an alternative
to these complex procedures, [11C]-mHED uptake is now
commonly quantified through a retention index, which is
defined as the ratio of the activity in the myocardium in the
final image of a 40- or 60-min dynamic sequence to the
integral of the image-derived arterial blood time–activity
curve. A volume of interest (VOI) for the input function is
placed in the basal plane; the VOI for tissue curves is place
within the left ventricle wall. Acquisition of [11C]-mHED
data can also be performed using ECG gating, for simul-
taneous analysis of LV volumes and contractility [27].
Since the myocardial uptake of [11C]-mHED is rela-
tively constant during the first 8 h after administration, this
retention index is very reliable. However, the blood pool
integral increases over time due to circulating metabolites.
The contribution of metabolites can be suppressed using a
correction method, when acquiring data at later time points
that 40- or 60-min post-injection [28]. Recent studies found
a close correlation between [11C]-mHED retention index
and late [123I-MIBG] heart-to-mediastinum rate [29].
Distribution of [11C]-mHED throughout left ventricular
myocardium in healthy normal individuals is regionally
homogeneous with high uptake in all myocardial segments
[30]. Therefore, the PET tracer [11C]-mHED is an attractive
non-invasive method to quantify the activity and distribu-
tion of sympathetic innervation. Visual interpretation of
bull’s eye plots, analogue to and alongside those of
myocardial perfusion, provides information for global
innervation status. However, when using the same
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17-segment model as in perfusion imaging analysis,
detailed information about perfusion–innervation relation-
ships can be obtained (Fig. 2). Mean [11C]-mHED retention
can be determined for those areas with both normal perfu-
sion ([80 % of the maximum myocardial blood flow) and
innervation ([75 % of the segment with maximum [11C]-
mHED retention), areas with a mismatch pattern: normal
perfusion and decreased cardiac sympathetic innervation
(\75 % of the segment with maximum [11C]-mHED
retention), and both abnormal perfusion (\80 % of the
maximum myocardial blood flow) and innervation (Fig. 3).
[11C]-CGP quantification
Before PET scanning, patients have to withdraw short
acting b-blockers. After injection of approximately
200 MBq of 11C-CGP, dynamic imaging will be per-
formed, and heart rate and blood pressure will be
monitored continuously. For kinetic data analysis of [11C]-
CGP tracers, no ‘simplified’ method as the retention index
is available (yet). Kinetic modelling of these postsynaptic
PET tracers, and thus quantification of b-adrenoceptor
density, is based on complex compartment models with
either dual- or triple-injection protocols, consisting of dif-
ferent doses of high and low specific activity [17, 31]. In
general, a first dose with a high specific activity will be
followed 20 min later by a second dose with added non-
radioactive ligand. A third injection consisting of non-ra-
dioactive ligand only is followed again 20 min later. Data
acquisition starts at the onset of the first injection. Arterial
blood samples are drawn during the first 20 min, and the
radioactivity in the plasma is determined with a gamma
counter. Radioactivity in the cellular fraction is calculated
using plasma and whole blood data, in combination with
the measured haematocrit value. The b-adrenoceptor den-
sity is eventually expressed as Bmax in pmol/g myocardial
tissue. Typically, b-adrenoceptor density is different
between heart failure patients and healthy control subjects.
For example, b-adrenoceptor density determined with
[11C]-CGP-12388 was significantly lower in six idiopathic
dilated cardiomyopathy patients compared to six age-
matched healthy volunteers (Fig. 4).
Relation pre- and postsynaptic sympathetic
imaging: [11C]-CGP-12177 versus [11C]-mHED
At present, only a few studies have combined the acqui-
sition of both the postsynaptic radiopharmaceutical [11C]-
Fig. 2 An example of a matched perfusion and innervation defect in
the inferoseptal wall of the left ventricle. a Polar map of rest nitrogen-
13 labelled ammonia PET, indicating myocardial infarction in the
inferoseptal wall, b polar map of [11C]-mHED uptake in the same
patient, with a defect in the same area as the myocardial infarction
Fig. 3 Flow charts showing the
summary of the acquisition
protocols of [11C]-mHED and
[11C]-CGP
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CGP-12177 and presynaptic radiopharmaceutical [11C]-
mHED in the same patient cohort and healthy control
subjects. In healthy controls, the distribution of both [11C]-
CGP-12177 and [11C]-mHED is homogeneous and well
matched [32]. In heart failure patients, both presynaptic
and postsynaptic functions are described significantly dif-
ferent from healthy control subjects. In addition, a mis-
match of [11C]-CGP-12177 versus [11C]-mHED uptake
(Fig. 5) can be found in severe heart failure patients [14]. A
(large) regional presynaptic defect with preserved postsy-
naptic b-adrenoceptor density is associated with worse
outcome, for example death, cardiac arrest or progressive
heart failure leading to transplantation. Also in patients
with hibernating myocardium after infarction, a reduction
in presynaptic uptake and postsynaptic b-adrenoceptor
density was observed [33]. In these patients, the observed
reduction was more global, in contrast to regional in
patients with heart failure. Finally, in patients with
arrhythmogenic right ventricular dysplasia/cardiomyopathy
b-adrenoceptor downregulation, but no presynaptic inner-
vation abnormality was reported [34]. This was suggested
to be caused by regional elevated levels of catecholamines,
leading to downregulation of b-adrenoceptors.
Quantification software
At present, commercially available software for kinetic
analysis of myocardial innervation PET tracers is rather
limited. For that reason, many centers performing inner-
vation PET studies have developed their own research
software. Software packages originally introduced for the
analysis and quantification of myocardial blood flow also
allow processing of other types of dynamically acquired
data, automatic segmentation of the myocardium and the
subsequent generation of time–activity curves. This soft-
ware enables regional analysis and replaces the concept of
manually drawing VOIs. Such packages include
FlowQuant, Carismas, and HOQUTO [35].
Future perspectives
Despite the strong properties of PET in general, non-in-
vasive imaging of the autonomic innervation of the heart
does not have a prominent role in clinical decision making
Fig. 4 Graph of the individual b-AR densities as measured with PET
for healthy controls (8.4 ± 1.5 pmol/g, n = 6) and patients with IDC
(5.4 ± 1.3 pmol/g, n = 6). This research was originally published in
Eur J Nucl Med Mol Imaging, re-used with permission [37]
Fig. 5 Short-axis PET images of [11C]-mHED (35- to 45-min sum)
and [11C]-CGP (10- to 20-min sum from injection 1) in CHF patient.
Apical slices are at upper left and basal slices are at lower right of
each panel. Arrows indicate extensive mismatch between [11C]-
mHED and [11C]-CGP. This research was originally published in
JNM. Caldwell JH, Link JM, Levy WC, Poole JE, Stratton JR.
Evidence for pre- to postsynaptic mismatch of the cardiac sympa-
thetic nervous system in ischemic congestive heart failure. J Nucl
Med. 2008;49:234–241.  by the Society of Nuclear Medicine and
Molecular Imaging, Inc
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thus far. However, the first large clinical trial (PAREPET)
showed that assessment of regional myocardial denervation
using [11C]-mHED predicts sudden cardiac death, inde-
pendently of ejection fraction or infarct volume [4]. This
can be considered as the step up to clinical implementation
of this promising imaging modality.
PET tracers have the unique ability to identify sympa-
thetic neurons by uptake and storage of tracers, and post-
synaptic receptor binding affinity. Until recently, ligands
for autonomic imaging had only labelled to radionuclides
with a short half-life, making it only possible to perform
imaging in those centers with an on-site cyclotron. The
recent introduction of [18F] labelled tracers for sympathetic
innervation will lead to the application of these tracers in
non-cyclotron centers. At present, no b-adrenoceptor sub-
type-specific [18F] labelled tracer has been developed yet,
and may be interesting for the near future. In addition, the
rapid developments in gallium-68 and copper-64 radio-
chemistry could be of additional value for imaging of
autonomic innervation in the future. However, this also
requires further investigation. Imaging of b-adrenoceptors
is complicated by application in a patient population that is
frequently treated with chronic b-adrenoceptor blockade.
This necessitates the development of novel tracers target-
ing intracellular second messengers and response elements
of the signal cascade.
As stated before, dedicated software packages for
dynamic data analysis are available, however, not specific
for autonomic myocardial quantification. Due to the rapid
developments in the field of innervation imaging, there is a
growing need for easy-to-use software packages for reli-
able visual and quantitative interpretation.
Future developments in the field of autonomic inner-
vation imaging should also focus on the cost-effectiveness
of implantable cardioverter-defibrillators (ICDs) in patients
with ischaemic cardiomyopathy. Since a minority of these
patients will develop ventricular arrhythmia, the clinical
need for better identification of patients who will benefit
from ICD therapy is undisputable. Determination of the
volume of denervated myocardial tissue using nuclear
medicine modalities plays an additional role in better risk
assessment of patients at risk for ventricular arrhythmia [4,
36]. Accordingly, imaging the extent of myocardial sym-
pathetic denervation could be able to better identify those
patients who will benefit from ICD therapy. With the help
of healthcare insurance agencies, the reduction of costs
from expensive ICDs can be achieved by imaging-based
identification of those patients.
Finally, the developments in hybrid imaging leading to
the simultaneous (or sequential) acquisition of PET and
magnetic resonance imaging (PET/MRI) data can provide a
further area of investigation with regard to tissue charac-
terisation. The combination of a regional defect on
sympathetic tracer imaging with either late gadolinium
enhancement or abnormal non-contrast T1 mapping could
potentially better identify the area of origin of ventricular
arrhythmia.
Conclusions
Non-invasive imaging of both pre- and postsynaptic sym-
pathetic innervation using different PET tracers is still
challenging and time consuming, due to complicated data
analysis and lacking dedicated software. Experience is, up
to present, mainly limited to centers with onsite cyclotrons.
However, the increasing number of studies showing the
additional value in cardiology, and the potential of a [18F]
labelled tracer make sympathetic innervation imaging very
attractive tool for further implementation in clinical deci-
sion making. To image b-adrenoceptors in cardiovascular
patient population that is frequently treated with chronic b-
adrenoceptor blockade, the development of novel tracers
targeting intracellular second messengers and response
elements of the signal cascade is needed.
Compliance with ethical standards
Conflict of interest Walter Noordzij and Riemer HJA Slart both
declare no conflict of interest. No funding was received for this
article.
Human and animal rights Research involving human participants
and/or animals.
Ethical approval This article does not contain any studies with
human participants or animals performed by any of the authors.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Werner RA, Rischpler C, Onthank D, Lapa C, Robinson S,
Sammnick S, Javadi M, Schwaiger M, Nekolla SG, Higuchi T
(2015) Retention kinetics of the 18F-labeled sympathetic nerve
PET tracer LMI1195: comparison with 11C-HED and 123I-
MIBG. J Nucl Med 56(9):1429–1433
2. Christensen TE, Kjaer A, Hasbak P (2014) The clinical value of
cardiac sympathetic imaging in heart failure. Clin Physiol Funct
Imaging 34:178–182
3. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS,
Lopez VA, Agostini D, Weiland F, Chandna H, Narula J,
ADMIRE-HF Investigators (2010) Myocardial iodine-123 meta-
iodobenzylguanidine imaging and cardiac events in heart failure.
Results of the prospective ADMIRE-HF (AdreView Myocardial
370 Clin Transl Imaging (2015) 3:365–372
123
Imaging for Risk Evaluation in Heart Failure) study. J Am Coll
Cardiol 55:2212–2221
4. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa
S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M,
Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional
myocardial sympathetic denervation predicts the risk of sudden
cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol
63:141–149
5. Investigators AVID (1999) Causes of death in the Antiarrhyth-
mics Versus Implantable Defibrillators (AVID) Trial. J Am Coll
Cardiol 34:1552–1559
6. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R,
Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE,
Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP,
Luceri RM, Ip JH, Sudden CardiacDeathin Heart Failure Trial
(SCD-HeFT) Investigators (2005) Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure. N Engl J
Med 352:225–237
7. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS,
Daubert JP, Higgins SL, Brown MW, Andrews ML, Trial Mul-
ticenter Automatic Defibrillator Implantation, Investigators II
(2002) Prophylactic implantation of a defibrillator in patients
with myocardial infarction and reduced ejection fraction. N Engl
J Med 346:877–883
8. Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao
PC, Schwaiger M, Wieland DM (1996) Clinical evaluation of
carbon-11-phenylephrine: MAO-sensitive marker of cardiac
sympathetic neurons. J Nucl Med 37:1923–1931
9. Tipre DN, Fox JJ, Holt DP, Green G, Yu J, Pomper M, Dannals
RF, Bengel FM (2008) In vivo PET imaging of cardiac presy-
naptic sympathoneuronal mechanisms in the rat. J Nucl Med
49:1189–1195
10. Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, Kagan M,
Yalamanchili P, Onthank D, Mistry M, Lazewatsky J, Broekema
M, Radeke H, Purohit A, Cdebaca M, Azure M, Cesati R,
Casebier D, Robinson SP (2011) Evaluation of LMI1195, a novel
18F-labeled cardiac neuronal PET imaging agent, in cells and
animal models. Circ Cardiovasc Imaging 4:435–443
11. Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu
YH, Sparks R, Puretskiy A, Lin SF, Crane P, Carson RE, Lee LV
(2014) Biodistribution and radiation dosimetry of LMI1195: first-
in-human study of a novel 18F-labeled tracer for imaging
myocardial innervation. J Nucl Med 55:1445–1451
12. Bohm M, Beuckelmann D, Brown L, Feiler G, Lorenz B,
Na¨bauer M, Kemkes B, Erdmann E (1988) Reduction of beta-
adrenoceptor density and evaluation of positive inotropic
responses in isolated, diseased human myocardium. Eur Heart J
9:844–852
13. Brodde OE, Hillemann S, Kunde K, Vogelsang M, Zerkowski HR
(1992) Receptor systems affecting force of contraction in the
human heart and their alterations in chronic heart failure. J Heart
Lung Transplant 11:S164–S174
14. Caldwell JH, Link JM, Levy WC, Poole JE, Stratton JR (2008)
Evidence for pre- to postsynaptic mismatch of the cardiac sym-
pathetic nervous system in ischemic congestive heart failure.
J Nucl Med 49:234–241
15. Elsinga PH, van Waarde A, Visser TJ, Vaalburg W (1998)
Visualization of b-adrenoceptors using PET. Clin Pos Imaging
1:81–94
16. Elsinga PH, Van Waarde A, Visser GM, Vaalburg W (1994)
Synthesis and preliminary evaluation of (R, S)-1-[2-((carbamoyl-
4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-[11C]-met hyl-4-triflu-
oromethyl-2-imidazolyl)phenoxy]-2-propanol ([11C]CGP 2071
2A) as a selective beta 1-adrenoceptor ligand for PET. Nucl Med
Biol 21:211–217
17. Doze P, Elsinga PH, van Waarde A, Pieterman RM, Pruim J,
Vaalburg W, Willemsen AT (2002) Quantification of beta-
adrenoceptor density in the human heart with (S)-
[11C]CGP12388 and a tracer kinetic model. Eur J Nucl Med Mol
Imaging 29:295–304
18. Law MP, Wagner S, Kopka K, Renner C, Pike VW, Schober O,
Scha¨fers M (2010) Preclinical evaluation of an 18F-labelled
beta1-adrenoceptor selective radioligand based on ICI 89,406.
Nucl Med Biol 37:517–552
19. Kenk M, Greene M, Thackeray J, deKemp RA, Lortie M, Thorn
S, Beanlands RS, DaSilva JN (2007) In vivo selective binding of
(R)-[11C]rolipram to phosphodiesterase-4 provides the basis for
studying intracellular cAMP signaling in the myocardium and
other peripheral tissues. Nucl Med Biol 34:71–77
20. Kenk M, Greene M, Lortie M, Dekemp RA, Beanlands RS,
Dasilva JN (2008) Use of a column-switching high-performance
liquid chromatography method to assess the presence of specific
binding of (R)- and (S)-[(11)C]rolipram and their labeled
metabolites to the phosphodiesterase-4 enzyme in rat plasma and
tissues. Nucl Med Biol 35:515–521
21. Thackeray JT, DaSilva JN, Elsinga PH (2015) Tracers for sym-
pathetic cardiac neurotransmission imaging. In: Slart RHJA, Tio
RA, Elsinga PH, Schwaiger M (eds) Autonomic innervation of
the heart, 1st edn. Springer, Heidelberg, pp 87–109
22. Go´mez-Vallejo V, Gonza´lez-Esparza M, Llop J (2012) Facile and
improved synthesis of[11C]MeQNB. J Labelled Comp Radio-
pharm 55:470–473
23. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ,
Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna
DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Hol-
laday MW, Williams M, Arneric SP (1996) A-85380 [3-(2(S)-
azetidinylmethoxy) pyridine]: in vitro pharmacological properties
of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine
receptor ligand. Neuropharmacology 35:725–734
24. DeGrado TR, Mulholland GK, Wieland DM, Schwaiger M
(1994) Evaluation of (-)[18F]fluoroethoxybenzovesamicol as a
new PET tracer of cholinergic neurons of the heart. Nucl Med
Biol 21:189–195
25. Egleton RD, Brown KC, Dasgupta P (2009) Angiogenic activity
of nicotinic acetylcholine receptors: implications in tobacco-re-
lated vascular diseases. Pharmacol Ther 121:205–223
26. Bucerius J, Manka C, Schmaljohann J, Mani V, Gu¨ndisch D,
Rudd JH, Bippus R, Mottaghy FM, Wu¨llner U, Fayad ZA,
Biersack HJ (2012) Feasibility of [18F]-2-Fluoro-A85380-PET
imaging of human vascular nicotinic acetylcholine receptors
in vivo. JACC Cardiovasc Imaging 5:528–536
27. Magota K, Hattori N, Manabe O, Naya M, Oyama-Manabe N,
Shiga T, Kuge Y, Yamada S, Sakakibara M, Yoshinaga K, Tamaki
N (2014) Electrocardiographically gated 11C-hydroxyephedrine
PET for the simultaneous assessment of cardiac sympathetic and
contractile functions. Ann Nucl Med 28:187–195
28. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gilder-
sleeve DL, Schwaiger M, Wieland DM (1990) Synthesis and
preliminary evaluation of carbon-11-meta-hydroxyephedrine: a
false transmitter agent for heart neuronal imaging. J Nucl Med
31:1328–1334
29. Matsunari I, Aoki H, Nomura Y, Takeda N, Chen WP, Taki J,
Nakajima K, Nekolla SG, Kinuya S, Kajinami K (2010) Iodine-123
metaiodobenzylguanidine imaging and carbon-11 hydrox-
yephedrine positron emission tomography compared in patientswith
left ventricular dysfunction. Circ Cardiovasc Imaging 3:595–603
30. Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E,
Hutchins GD, Deeb M, Wolfe E Jr, Wieland DM (1990) Non-
invasive evaluation of sympathetic nervous system in human
heart by positron emission tomography. Circulation 82:457–464
Clin Transl Imaging (2015) 3:365–372 371
123
31. Delforge J, Mesangeau D, Dolle F, Merlet P, Loc’h C, Bott-
laender M, Trebossen R, Syrota A (2002) In vivo quantification
and parametric images of the cardiac beta-adrenergic receptor
density. J Nucl Med 43:215–226
32. Link JM, Stratton JR, Levy W, Poole JE, Shoner SC, Stuetzle W,
Caldwell JH (2003) PET measures of pre- and post-synaptic
cardiac beta adrenergic function. Nucl Med Biol 30:795–803
33. John AS, Mongillo M, Depre C, Khan MT, Rimoldi OE, Pepper
JR, Dreyfus GD, Pennell DJ, Camici PG (2007) Pre- and post-
synaptic sympathetic function in human hibernating myocardium.
Eur J Nucl Med Mol Imaging 34:1973–1980
34. Wichter T, Scha¨fers M, Rhodes CG, Borggrefe M, Lerch H,
Lammertsma AA, Hermansen F, Schober O, Breithardt G,
Camici PG (2000) Abnormalities of cardiac sympathetic inner-
vation in arrhythmogenic right ventricularcardiomyopathy:
quantitative assessment of presynaptic norepinephrine reuptake
and postsynaptic beta-adrenergic receptor density with positron
emission tomography. Circulation 101(13):1552–1558
35. Nekolla SG, Rischpler C (2015) General principles of PET/CT
and autonomic innervation of the heart including kinetics and
software. In: Slart RHJA, Tio RA, Elsinga PH, Schwaiger M
(eds) autonomic innervation of the heart, 1st edn. Springer,
Heidelberg, pp 161–185
36. Sweeney MO, Ruskin JN (1994) Mortality benefits and the
implantable cardioverter-defibrillator. Circulation 89:1851–1858
37. De Jong RM, Willemsen AT, Slart RH, Blanksma PK, van
Waarde A, Cornel JH, Vaalburg W, van Veldhuisen DJ, Elsinga
PH (2005) Myocardial beta-adrenoceptor downregulation in
idiopathic dilated cardiomyopathy measured in vivo with PET
using the new radioligand (S)-[11C]CGP12388. Eur J Nucl Med
Mol Imaging 32:443–447
372 Clin Transl Imaging (2015) 3:365–372
123
